Skip to main content
. 2020 Jan 8;4:108. Originally published 2019 Jul 17. [Version 4] doi: 10.12688/wellcomeopenres.15314.4

Table 7. Incremental cost-effectiveness results – base case and sensitivity analysis.

Analysis Intravenous
Mean costs
(SE)
Oral
Mean
costs (SE)
Difference (95%
confidence
interval)
Intravenous
Mean QALYs
(SE)
Oral Mean
QALYs
(SE)
Difference (95%
confidence
interval)
Incremental
cost per QALY
Base case (Multiple
imputation)
£13,274
(£446)
£10,534
(£453)
£2,740
(£1,488 to £3,992)
0.537
(0.013)
0.545
(0.015)
-0.007
(-0.045 to 0.031)
Oral antibiotics
dominant
Complete case £13,275
(£10,113)
£10,549
(10,371)
£2,727
(£1,473 to £3,980)
0.558
(0.265)
0.535
(0.300)
0.023
(–0.036 to 0.081)
Oral antibiotics
dominant
Mean imputation
costs
£13,141
(£10,036)
£10,406
(£10,269)
£2,735
(£1,508 to £3,963)
0.537
(0.013)
0.545
(0.015)
-0.007
(-0.045 to 0.031)
Oral antibiotics
dominant
District Nurse costs
for all missing OPAT
types
£13,274
(£448)
£10,657
(£463)
£2,617
(£1,354 to £3,880)
0.537
(0.013)
0.545
(0.015)
-0.007
(-0.045 to 0.031)
Oral antibiotics
dominant
Self-administration
costs for all missing
OPAT types
£13,230
(£442)
£10,343
(£448)
£2,887
(£1,656 to £4,118)
0.537
(0.013)
0.545
(0.015)
-0.007
(-0.045 to 0.031)
Oral antibiotics
dominant

QALYs, quality-adjusted life years; SE, standard error; OPAT, outpatient parenteral antimicrobial therapy.

‡Difference between arms was calculated using a generalized linear model